Ignite Creation Date:
2024-05-05 @ 11:53 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00162006
Status:
COMPLETED
Last Update Posted:
2021-05-03
First Post:
2005-09-08
Brief Title:
Efficacy and Safety Study of a 10 Triple Virally Reduced Intravenous Immune Globulin Solution in Adult Subjects With Chronic Idiopathic Thrombocytopenic Purpura
Sponsor:
Baxalta now part of Shire
Organization:
Takeda
Study Overview
Official Title:
Prospective Open-Label Study of the Efficacy and Safety of Immune Globulin Intravenous Human 10 TVR Solution in Adult Subjects With Chronic Idiopathic Thrombocytopenic Purpura
Status:
COMPLETED
Status Verified Date:
2021-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate whether Immune Globulin Intravenous Human 10 TVR Triple Virally Reduced Solution is an effective and safe treatment in patients with chronic idiopathic thrombocytopenic purpura
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None